Phase I Trial Evaluating Cisplatin, Gemcitabine and Veliparib in Two Patient Cohorts: Germline-BRCA Mutation Carriers and BRCA Wild-Type Pancreas Ductal Adenocarcinoma

BACKGROUND: We performed a phase I trial evaluating a combination of cisplatin, gemcitabine, and escalating doses of veliparib in patients with untreated advanced pancreas adenocarcinoma (PDAC) in two cohorts: germline mutated BRCA 1/2 (BRCA+) and wild-type BRCA (BRCA−). Aims were to determine the s...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer
Hlavní autoři: O’Reilly, Eileen M., Lee, Jonathan W., Lowery, Maeve A., Capanu, Marinela, Stadler, Zsofia K., Moore, Malcolm J., Dhani, Neesha, Kindler, Hedy L., Estrella, Hayley, Maynard, Hannah, Golan, Talia, Segal, Amiel, Salo-Mullen, Erin E., Yu, Kenneth H., Epstein, Andrew S., Segal, Michal, Brenner, Robin, Do, Richard K., Chen, Alice P., Tang, Laura H., Kelsen, David P.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5867226/
https://ncbi.nlm.nih.gov/pubmed/29338080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31218
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky